US Stock MarketDetailed Quotes
SNPX Synaptogenix
- 4.3300
- -0.3300-7.08%
Close Apr 19 16:00 ET
- 4.3100
- -0.0200-0.46%
Post 18:08 ET
4.70MMarket Cap-146P/E (TTM)
4.7100High4.2520Low29.91KVolume4.6400Open4.6600Pre Close132.99KTurnover2.83%Turnover RatioLossP/E (Static)1.09MShares47.000052wk High0.19P/B4.58MFloat Cap3.527552wk Low--Dividend TTM1.06MShs Float362.5000Historical High--Div YieldTTM9.83%Amplitude3.5250Historical Low4.4470Avg Price1Lot Size
About Synaptogenix Company
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.
Company Profile
SymbolSNPX
Company NameSynaptogenix
Listing DateJun 7, 2021
Founded2012
CEOMr. Alan J. Tuchman, M.D.
MarketNASDAQ
Employees5
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address1185 Avenue of the Americas,3rd floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036
Phone1-973-242-0005
Websitehttp://www.synaptogen.com
Company Executives
- Name
- Position
- Salary
- Alan J. Tuchman, M.D.
- Director and Chief Executive Officer
- 749.64K
- Robert Weinstein
- Chief Financial Officer, Secretary, Treasurer, Principal Accounting Officer and Executive Vice President
- 883.34K
- Daniel L. Alkon, M.D.
- Director, President and Chief Scientific Officer
- 812.46K
- William S. Singer
- Vice-Chairman of the Board
- 442.46K
- Joshua Nathaniel Silverman
- Chairman of the Board
- 602.46K
- Jonathan L. Schechter
- Independent Director
- 387.96K
- Bruce T. Bernstein
- Independent Director
- 402.46K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg